Modern use of 5-aminosalicylic acid compounds for ulcerative colitis

References

• Le Berre C, Ananthakrishnan AN, Danese S, et al. Ulcerative colitis and crohn’s disease have the similar burden and goals for treatment. Clin Gastroenterol Hepatol. 2019 Jul 10. pii: S1542-3565(19)30738-4. doi: 10.1016/j.cgh.2019.07.005
   Google Scholar
• Svartz N. Ett nytt sulfonamidpreparat. Forelopande meddelande. Nord Med. 1941;9:544.
   Google Scholar
• Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962;279:1094–1096.
   Google Scholar
• Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973;289:491–495.
   PubMed Web of Science ®Google Scholar
• Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet Lond Engl. 1977;2:892–895.
   PubMed Web of Science ®Google Scholar
• Nielsen HO, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol. 1983;16:738–740.
   PubMed Web of Science ®Google Scholar
• Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196–200.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29–42.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.
   PubMed Web of Science ®Google Scholar
• Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991;115:350–355.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa study group. Am J Gastroenterol. 1993;88:1188–1197.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
   PubMed Web of Science ®Google Scholar
• Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23:841–855.
   PubMed Web of Science ®Google Scholar
• Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohnʼs disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:617–629.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Chande N, MacDonald JK. Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from cochrane reviews. Inflamm Bowel Dis. 2013;19:2031–2040.
   PubMed Web of Science ®Google Scholar
• Wang Y, Parker CE, Bhanji T, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Petrillo M, Molteni P, et al. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. J Clin Gastroenterol. 1995;21:287–289.
   PubMed Web of Science ®Google Scholar
• Forbes A, Al-Damluji A, Ashworth S, et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2005;21:1099–1104.
   PubMed Web of Science ®Google Scholar
• Meyers S, Sachar DB, Present DH, et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987;93:1255–1262.
   PubMed Web of Science ®Google Scholar
• Green JRB, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther. 2002;16:61–68.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–784.
   PubMed Web of Science ®Google Scholar
• Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156:748–764.
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane MS, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004115.
   Google Scholar
• van Bodegraven AA, Boer RO, Lourens J, et al. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther. 1996;10:327–332.
   PubMed Web of Science ®Google Scholar
• Andus T, Kocjan A, Müser M, et al. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010;16:1947–1956.
   PubMed Web of Science ®Google Scholar
• Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011;56:513–522.
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–781.
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Fockens P, Meijer JW, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996;8:549–553.
   PubMed Web of Science ®Google Scholar
• Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2011;33:996–1009.
   PubMed Web of Science ®Google Scholar
• Pimpo MT, Galletti B, Palumbo G, et al. Mesalazine vanishing time from rectal mucosa following its topical administration. J Crohns Colitis. 2010;4:102–105.
   PubMed Web of Science ®Google Scholar
• Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867–1871.
   PubMed Web of Science ®Google Scholar
• Pica R, Paoluzi OA, Iacopini F, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis. 2004;10:731–736.
   PubMed Web of Science ®Google Scholar
• Choi YS, Kim WJ, Kim JK, et al. Efficacy of topical 5-aminosalicylate monotherapy in patients with ulcerative proctitis with skip inflammation. J Gastroenterol Hepatol. 2018;33:1200–1206.
   PubMed Web of Science ®Google Scholar
• Ford AC, Khan KJ, Achkar J-P, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:167–176. author reply 177.
   PubMed Web of Science ®Google Scholar
• Cortot A, Maetz D, Degoutte E, et al. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol. 2008;103:3106–3114.
   PubMedGoogle Scholar
• Römkens TEH, Kampschreur MT, Drenth JPH, et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012;18:2190–2198.
   PubMed Web of Science ®Google Scholar
• Paoluzi P, D’Albasio G, Pera A, et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2002;34:787–793.
   Google Scholar
• Feagan BG, MacDonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:1785–1794.
   PubMed Web of Science ®Google Scholar
• Flourié B, Hagège H, Tucat G, et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther. 2013;37:767–775.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384.
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;11:CD004118.
   PubMedGoogle Scholar
• d’Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997;92:1143–1147.
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis. 2007;13:1115–1120.
   PubMed Web of Science ®Google Scholar
• Leifeld L, Pfützer R, Morgenstern J, et al. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis. Aliment Pharmacol Ther. 2011;34:1115–1122.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX multi matrix system mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007;26:205–215.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.
   PubMed Web of Science ®Google Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16:343–356.e3.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960;1:217–222.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J. 1962;2:1708–1711.
   PubMed Web of Science ®Google Scholar
• Wang Y, Parker CE, Feagan BG, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016 May 9;(5):CD000544.
   Web of Science ®Google Scholar
• Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9:483–489.e3.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126–137.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.
   PubMed Web of Science ®Google Scholar
• Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016 May 18;(5):CD000478.
   Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265.e3.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95. quiz e14-15.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96–109.e1.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
   PubMed Web of Science ®Google Scholar
• Battat R, Duijvestein M, Guizzetti L, et al. Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Am J Gastroenterol. 2019;114:733–745.
   PubMed Web of Science ®Google Scholar
• Sehgal P, Colombel J-F, Aboubakr A, et al. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018;47:1597–1609.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Luna M, González-Lama Y, et al. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol Hepatol. 2008;31:477–484.
   PubMedGoogle Scholar
• Muller AF, Stevens PE, McIntyre AS, et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther. 2005;21:1217–1224.
   PubMed Web of Science ®Google Scholar
• Heap GA, So K, Weedon M, et al. Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease. J Crohns Colitis. 2016;10:149–158.
   PubMed Web of Science ®Google Scholar
• van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second european evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107–124.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Gastroenterology. 2019;156:1508–1524.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14:348–354.e17.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Whitman CB, Spiegel BMR, et al. Development of an index to define overall disease severity in IBD. Gut. 2018;67:244–254.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Jung ES, Lee JH, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Hepatogastroenterology. 2012;59:1415–1420.
   PubMed Web of Science ®Google Scholar
• Bello C, Belaiche J, Louis E, et al. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011;5:196–202.
   PubMed Web of Science ®Google Scholar
• Dias CC, Rodrigues PP, da Costa-Pereira A, et al. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9:156–163.
   PubMed Web of Science ®Google Scholar
• Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016;10:1385–1394.
   PubMed Web of Science ®Google Scholar
• Cross RK. Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2017;23:1689–1701.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet Lond Engl. 2009;374:1617–1625.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621–1628.e1-5.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14:1385–1397.e10.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol J Can Gastroenterol. 2007;21:827–834.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478–2485.
   PubMed Web of Science ®Google Scholar
• Orchard TR, van der Geest SAP, Travis SPL. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question. Aliment Pharmacol Ther. 2011;33:1028–1035.
   PubMed Web of Science ®Google Scholar
• Hiwatashi N, Suzuki Y, Mitsuyama K, et al. Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol. 2011;46:46–56.
   PubMed Web of Science ®Google Scholar
• Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment Pharmacol Ther. 2008;28:1287–1296.
   PubMed Web of Science ®Google Scholar
• Pillai N, Dusheiko M, Burnand B, et al. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. Green J, editor. PLoS One. 2017;12:e0185500.
   PubMed Web of Science ®Google Scholar
• Doherty G, Katsanos KH, Burisch J, et al. European Crohn’s and colitis organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease. J Crohns Colitis. 2018;12:17–31.
   PubMed Web of Science ®Google Scholar
• Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther. 2010;31:202–209.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Lytras T, et al. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1179–1192.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Gulamhusein A, Bernstein CN. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012;107:1298–1304. quiz 1297, 1305.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Sandborn WJ, Gupta S. Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management. Cancer Prev Res Phila Pa. 2016;9:887–894.
   PubMed Web of Science ®Google Scholar
• Lu MJ, Qiu XY, Mao XQ, et al. Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:318–331.
   PubMed Web of Science ®Google Scholar
• OʼConnor A, Packey CD, Akbari M, et al. Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: an agent-specific systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:2562–2569.
   PubMed Web of Science ®Google Scholar
• Flores BM, O’Connor A, Moss AC. Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. Gastrointest Endosc. 2017;86:1006–1011.e8.
   PubMed Web of Science ®Google Scholar
• Saxena AP, Limdi JK, Farraye FA. Zeroing in on endoscopic and histologic mucosal healing to reduce the risk of colorectal neoplasia in inflammatory bowel disease. Gastrointest Endosc. 2017;86:1012–1014.
   PubMed Web of Science ®Google Scholar
• Gilissen LPL, Bierau J, Derijks LJJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2005;22:605–611.
   PubMed Web of Science ®Google Scholar
• Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol. 1995;39:456–459.
   PubMed Web of Science ®Google Scholar
• Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006;12:251–257.
   PubMed Web of Science ®Google Scholar
• de Boer NKH, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007;102:2747–2753.
   PubMed Web of Science ®Google Scholar
• Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol. 2001;13:1297–1301.
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004;99:1122–1128.
   PubMed Web of Science ®Google Scholar
• Roth R, Schreiner P, Rossel J-B, et al. P604 Biologics with or without a combination with 5-ASA in ulcerative colitis: frequency of usage and effect on the course of disease in the Swiss IBD-cohort study. J Crohns Colitis. 2019;13:S418–S418.
   Web of Science ®Google Scholar
• Singh S, Proudfoot JA, Dulai PS, et al. No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol. 2018;113:1197–1205.
   PubMed Web of Science ®Google Scholar
• Ungaro RC, Limketkai BN, Jensen CB, et al. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2019;68:977–984.
   PubMed Web of Science ®Google Scholar
• Assisi RF, GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol. 2008;54:231–238.
   PubMedGoogle Scholar
• Vernia P, Monteleone G, Grandinetti G, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci. 2000;45:976–981.
   PubMed Web of Science ®Google Scholar
• Liang H-L, Ouyang Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol. 2008;14:114–119.
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit Int Med J Exp Clin Res. 2004;10:PI126–131.
   Google Scholar
• Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929–2933.
   PubMed Web of Science ®Google Scholar
• Loftus EV. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12:1107–1113.
   PubMed Web of Science ®Google Scholar
• Lachaine J, Yen L, Beauchemin C, et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol. 2013;13:23.
   PubMed Web of Science ®Google Scholar
• Goodhand JR, Kamperidis N, Sirwan B, et al. Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:1097–1108.
   PubMed Web of Science ®Google Scholar
• Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19:1528–1533.
   PubMed Web of Science ®Google Scholar
• Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32:983–1028.
   PubMed Web of Science ®Google Scholar
• Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39–43.
   PubMed Web of Science ®Google Scholar
• Khan N, Abbas AM, Bazzano LA, et al. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther. 2012;36:755–764.
   PubMed Web of Science ®Google Scholar
• Kane SV, Brixner D, Rubin DT, et al. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm JMCP. 2008;14:s2–12. quiz s13-15.
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis–strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008;27:1157–1166.
   PubMed Web of Science ®Google Scholar
• Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191–198.
   PubMed Web of Science ®Google Scholar
• Keil R, Wasserbauer M, Zádorová Z, et al. Adherence, risk factors of non-adherence and patient’s preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol. 2018;53:459–465.
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Okaniwa N, Mizuno M, et al. Treatment adherence in patients with ulcerative colitis is dependent on the formulation of 5-aminosalicylic acid. Digestion. 2019;99(2):133–139.
   Google Scholar
• Kawakami A, Tanaka M, Ochiai R, et al. Difficulties in performing mesalazine enemas and factors related to discontinuation among patients with ulcerative colitis. Gastroenterol Nurs Off J Soc Gastroenterol Nurses Assoc. 2017;40:101–108.
   Google Scholar
• Limdi JK, Vasant DH. Anorectal dysfunction in distal ulcerative colitis: challenges and opportunities for topical therapy. J Crohns Colitis. 2016;10:503.
   PubMed Web of Science ®Google Scholar
• Rao SS, Read NW, Davison PA, et al. Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology. 1987;93:1270–1275.
   PubMed Web of Science ®Google Scholar
• Alp MH, Sage MR, Grant AK. The significance of widening of the presacral space at contrast radiography in inflammatory bowel disease. Aust N Z J Surg. 1978;48:175–177.
   PubMedGoogle Scholar
• Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther. 2001;15:53–62.
   PubMed Web of Science ®Google Scholar
• Bokemeyer B, Hommes D, Gill I, et al. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J Crohns Colitis. 2012;6:476–482.
   PubMed Web of Science ®Google Scholar
• Gillespie D, Hood K, Farewell D, et al. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. Inflamm Bowel Dis. 2014;20:82–91.
   PubMed Web of Science ®Google Scholar
• Connolly MP, Kuyvenhoven JP, Postma MJ, et al. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing. J Crohns Colitis. 2014;8:357–362.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Sandborn WJ, Zou G, et al. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017;46:292–302.
   PubMed Web of Science ®Google Scholar
• Dignass A, Schnabel R, Romatowski J, et al. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United Eur Gastroenterol J. 2018;6:138–147.
   PubMed Web of Science ®Google Scholar
• Sun J, Yuan Y. Mesalazine modified-release tablet in the treatment of ulcerative colitis in the remission phase: a chinese, multicenter, single-blind, randomized controlled study. Adv Ther. 2016;33:410–422.
   PubMed Web of Science ®Google Scholar
• Eliakim R, Tulassay Z, Kupcinskas L, et al. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26:1237–1249.
   PubMed Web of Science ®Google Scholar
• Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20:2276–2285.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Sands BE, Panaccione R, et al. OP37 efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: week 44 results from UNIFI. J Crohns Colitis. 2019;13:S025–S026.
   Web of Science ®Google Scholar
• Jusué V, Chaparro M, Gisbert JP. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2018;50:353–359.
   Google Scholar